Sign Up

About ARALAST NP Therapy

ARALAST NP ARALAST NP

Patient Kits and Brochures

ARALAST Patient Education Kit

AATD Patient Education Kit

The ARALAST NP Patient Education Kit is designed to help people living with AAT deficiency. Baxter is pleased to provide this packet of useful information about the diagnosis, treatment, and management of this condition as another service to the Alpha-1 community.

In the kit, you will find a wealth of print materials to help you with all aspects of living with Alpha-1, including these booklets:

  • Getting Started with Augmentation Therapy
  • About Alpha-1 Antitrypsin (AAT) Deficiency
  • Reimbursement Q & A
  • The Alpha-1 Security Program

Plus, the kit includes a Health Diary and a CD of relaxation music.

Order ARALAST NP Patient Education Kit

You or your patients may order a Patient Education Kit online or by phone at 1-866-ARALAST (272-5278).

ARALAST NP Patient Brochure

Alpha-1 Antitrypsin (AAT) Deficiency: What it means and what you can do

This booklet is aimed at patients and families curious to learn more about AAT deficiency. This guide has information for everyone, including those considering testing, those recently diagnosed, and those just looking for more information on AAT deficiency.

The brochure covers the following topics:

  • What is AAT deficiency?
  • The screening and testing process
  • What treatment might your doctor recommend?
  • AAT augmentation with ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]
  • Who you can contact for additional help
  • Taking charge
  • A helpful glossary of terms
Order ARALAST NP Patient Brochure

You may order the AATD Patient Brochure online or by phone at 1-866-ARALAST (272-5278).

You may also download a copy of the brochure.

ARALAST NP [Alpha1-Proteinase Inhibitor (Human)]

ARALAST NP is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST NP is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.

Please review the Important Risk Information and the Full Prescribing Information

Please review the Important Risk Information and the Full Prescribing Information